US Asset Management LLC Sells 77 Shares of Amgen Inc. (NASDAQ:AMGN)

US Asset Management LLC reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 3.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,003 shares of the medical research company’s stock after selling 77 shares during the quarter. US Asset Management LLC’s holdings in Amgen were worth $522,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Centricity Wealth Management LLC bought a new stake in Amgen during the fourth quarter worth approximately $25,000. Ritter Daniher Financial Advisory LLC DE increased its stake in Amgen by 66.2% during the fourth quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company’s stock worth $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC bought a new stake in Amgen during the fourth quarter worth approximately $34,000. Atala Financial Inc bought a new stake in Amgen during the fourth quarter worth approximately $34,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen during the fourth quarter worth approximately $36,000. 76.50% of the stock is owned by institutional investors.

Amgen Stock Up 0.2%

Shares of NASDAQ:AMGN opened at $271.90 on Friday. Amgen Inc. has a 52-week low of $253.30 and a 52-week high of $346.85. The stock has a market cap of $146.20 billion, a P/E ratio of 36.01, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The business’s 50 day moving average is $287.76 and its 200 day moving average is $287.05. The company has a quick ratio of 0.95, a current ratio of 1.26 and a debt-to-equity ratio of 9.62.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, May 1st. The medical research company reported $4.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a return on equity of 176.32% and a net margin of 12.24%. The company had revenue of $8.15 billion for the quarter, compared to analysts’ expectations of $8.05 billion. During the same quarter in the prior year, the firm earned $3.96 earnings per share. Amgen’s revenue was up 9.4% compared to the same quarter last year. Sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Shareholders of record on Friday, May 16th will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $9.52 dividend on an annualized basis and a yield of 3.50%. Amgen’s dividend payout ratio is currently 86.86%.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. Guggenheim assumed coverage on Amgen in a research note on Tuesday. They set a “neutral” rating and a $288.00 price objective on the stock. Piper Sandler cut their target price on Amgen from $329.00 to $328.00 and set an “overweight” rating on the stock in a research note on Friday, May 16th. UBS Group reaffirmed a “neutral” rating and set a $315.00 target price (down previously from $319.00) on shares of Amgen in a research note on Friday, May 2nd. Johnson Rice set a $294.00 target price on Amgen in a research note on Wednesday, March 5th. Finally, Erste Group Bank cut Amgen from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 8th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $309.22.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.